uniQure price target raised to $20 from $7 at Mizuho

Mizuho raised the firm’s price target on uniQure (QURE) to $20 from $7 and keeps a Neutral rating on the shares. The firm cites increased confidence in AMT-130 to obtain accelerated approval in Huntington’s disease, given the alignment the company reached with the FDA, for the target increase. The firm, however, has questions about the potential AMT-130 adoption given the complex administration, challenging gene therapy adoption and reimbursement landscape, and competitive development landscape.